Eupraxia Pharmaceuticals (EPRX)
EPRX · BiotechSign PipelinePipeline Overview
- Therapeutic Focus
- Extended Release GI/Dermsrc
Signal Snapshot
1
Clinical Trial (ClinicalTrials.gov aggregate)
0
Catalyst Records
5
Publications on Record
1 Phase 1, 1 Phase 2
Trial Phase Mix
ClinicalTrials.gov aggregate as of 2026-09-29. Source
Recent Publications
- The impact of global recruitment and country income on placebo rates in inflammatory bowel disease clinical trials. — J Crohns Colitis (2026) PMID 42357952
- Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial. — Lancet Gastroenterol Hepatol (2026) PMID 42341804
5 total publications tracked — view all on BiotechSign
Get real-time catalyst alerts, analyst signals, dilution risk scores, and full pipeline data for Eupraxia Pharmaceuticals.
Full EPRX Data Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.